Skip to content

Acorda Therapeutics, Inc.

CIK 0001008848

← back to feed
Revenue (TTM)
$99.94M
−0.8% YoY Q1 May 2024
Net Income (TTM)
−$62.49M
−283.6% YoY Q1 May 2024
EPS Diluted (TTM)
−$50.31
−212.1% YoY Q1 May 2024
Gross Margin
41.9%
Q1 May 2024
Operating Margin
-37.3%
Q1 May 2024
Net Margin
-62.5%
Q1 May 2024
Free Cash Flow (TTM)
−$94.7M
Q1 May 2024
Cash
$9.36M
Q1 May 2024
Total Debt
$39K
Q1 May 2024
Shares Outstanding
1.24M sh
Q1 May 2024

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings